Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.
about
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cellsRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveDo the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?Statins as modulators of bone formation.The Interaction Between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination TherapyStatin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trialsDifferential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sitesAcute simvastatin inhibits K ATP channels of porcine coronary artery myocytesTargeted delivery of lovastatin and tocotrienol to fracture site promotes fracture healing in osteoporosis model: micro-computed tomography and biomechanical evaluationRole of angiogenesis in endodontics: contributions of stem cells and proangiogenic and antiangiogenic factors to dental pulp regenerationLovastatin induces relaxation and inhibits L-type Ca(2+) current in the rat basilar artery.Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase InhibitorsComparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.Caveolin contributes to the modulation of basal and β-adrenoceptor stimulated function of the adult rat ventricular myocyte by simvastatin: a novel pleiotropic effectStatins and breast cancer prognosis: evidence and opportunities.Statin use and risk of breast cancer: a meta-analysis of observational studies.Statin use and risk of bladder cancer: a meta-analysis.Rhabdomyolysis and HMG-CoA reductase inhibitors.Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies.Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.Statins and risk of cancer: a systematic review and metaanalysis.Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.Pharmacological effects of lipid-lowering drugs on circulating adipokines.Statin use and decline in gait speed in community-dwelling older adultsSimvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape.Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials.New lipid-modifying therapies.Chemopreventive strategies in hepatocellular carcinomaPharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism.Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.H2O2: a Ca(2+) or Mg(2+)-sensing function in statin passive diffusion.Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry.Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations.Effects of statin use on volumetric mammographic density: results from the KARMA study.3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase.Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study.Systematic review with network meta-analysis: statins and risk of hepatocellular carcinomaEffect of levels of acetate on the mevalonate pathway of Borrelia burgdorferi
P2860
Q21093314-00513646-58B0-4FA4-8B48-DEC00B77F5C1Q24594814-EB23BECF-AED3-42FA-ADAF-995124E62DABQ24804153-1271BFAC-F71A-4620-8A6D-58E3D380A1B0Q24806116-B5551A26-9045-43E3-9298-A4D6E5FC4AF4Q26771168-4491C661-FE0D-489B-978E-00ABF5E342CAQ26864662-C8E24AA6-405D-486E-99F3-A24DB4EADBD1Q28478551-6398B18A-3CA0-478A-BAA3-ADBFD0EEA9BEQ28533966-EDB90860-5450-4B9B-AACC-1A3EDCED4621Q28542781-46D9A548-4787-4876-8F22-3E07EBBDE0A0Q28817681-5BAE48BB-0127-41C8-832B-1C948E64CFDFQ30981445-8A3DE643-5BF7-403A-B3F3-6173B423FF00Q33763342-334AFEE6-A999-4B77-B23F-A5760128DA2DQ33826357-4B4E63A9-3DEE-4704-89FD-316F65130A64Q33891588-5B12EF73-BA5B-4F4C-9921-B09CB0CD8923Q34166022-8D5291C9-3A24-49BB-A950-CA5947956F54Q34206487-F7234D4F-35E6-403F-87A7-07BEF9A83B06Q34288756-5E5E063A-5ABC-4C12-9F69-8E866E11F435Q34325144-3B236059-931F-47A0-8758-196EFC2D2DF3Q34382555-8A902ABD-E2BD-497C-AA7D-2D5E4176DD5CQ34387037-5715DCD0-9CE9-4447-820A-66063D219E69Q34556705-FA9C254B-ED5E-4A73-949C-0FFC82BD2143Q34585294-D6C1696B-AE89-4B17-8301-18E173F2D357Q34618889-93982F91-6537-44AE-9B9E-1A230F2D9E66Q34877922-39561958-48CA-4428-AFF7-8B832A2E054DQ34989719-651E4604-8636-4D23-8A6D-D9D50C67647AQ35005659-7EB6AAE8-483E-4ADD-A97B-79C499E96886Q35035835-5AEF5BC7-D76B-462D-B061-E44FC4E655A7Q35073322-E67ED135-3CC4-4326-A8FF-94E33406A4E5Q35101365-56D965CC-F607-4472-B021-BD5C7122A865Q35127790-3C5ACD30-6A6B-433E-9107-7EE4A8840048Q35237250-C29DC2A6-B8F2-4951-AD08-6A73831708C5Q35268601-0AA01843-7073-409C-B5BA-9132ABF92207Q35553907-67DBB269-040C-42F2-AEDB-62B0E6D0B55CQ35639538-106A68EC-4C3B-4E96-87B8-D0D314E0D929Q35642416-20880EDC-4065-4654-B4F4-551FB1F2F8B9Q35643266-3119818D-C43B-44F0-8E60-AA54C4432473Q35654989-50499E58-5873-42F7-8E7F-7FAC318AE6DAQ35901096-289A5B29-788F-46D3-B126-FF8611F3F937Q35946029-413938A8-7FCC-4E66-93E3-FFC29CD68FE7Q36000800-C9BCCF13-A453-4262-B8AF-F42E8DAA21BE
P2860
Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@ast
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@en
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@nl
type
label
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@ast
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@en
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@nl
prefLabel
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@ast
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@en
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@nl
P1476
Hydrophilicity/lipophilicity: ...... HMG-CoA reductase inhibitors.
@en
P2093
P356
10.1016/S0165-6147(97)01147-4
P577
1998-01-01T00:00:00Z